1. Home
  2. MEIP vs MXC Comparison

MEIP vs MXC Comparison

Compare MEIP & MXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • MXC
  • Stock Information
  • Founded
  • MEIP 2000
  • MXC 1972
  • Country
  • MEIP United States
  • MXC United States
  • Employees
  • MEIP N/A
  • MXC N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • MXC Oil & Gas Production
  • Sector
  • MEIP Health Care
  • MXC Energy
  • Exchange
  • MEIP Nasdaq
  • MXC Nasdaq
  • Market Cap
  • MEIP 13.3M
  • MXC 13.3M
  • IPO Year
  • MEIP 2003
  • MXC N/A
  • Fundamental
  • Price
  • MEIP $2.16
  • MXC $6.97
  • Analyst Decision
  • MEIP Hold
  • MXC
  • Analyst Count
  • MEIP 1
  • MXC 0
  • Target Price
  • MEIP N/A
  • MXC N/A
  • AVG Volume (30 Days)
  • MEIP 6.0K
  • MXC 3.3K
  • Earning Date
  • MEIP 05-13-2025
  • MXC 06-26-2025
  • Dividend Yield
  • MEIP N/A
  • MXC 1.52%
  • EPS Growth
  • MEIP N/A
  • MXC N/A
  • EPS
  • MEIP N/A
  • MXC 0.63
  • Revenue
  • MEIP N/A
  • MXC $7,161,739.00
  • Revenue This Year
  • MEIP N/A
  • MXC N/A
  • Revenue Next Year
  • MEIP N/A
  • MXC N/A
  • P/E Ratio
  • MEIP N/A
  • MXC $10.54
  • Revenue Growth
  • MEIP 33.76
  • MXC 2.12
  • 52 Week Low
  • MEIP $1.46
  • MXC $5.89
  • 52 Week High
  • MEIP $4.10
  • MXC $14.11
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 60.32
  • MXC 35.81
  • Support Level
  • MEIP $2.01
  • MXC $6.41
  • Resistance Level
  • MEIP $2.08
  • MXC $6.97
  • Average True Range (ATR)
  • MEIP 0.10
  • MXC 0.37
  • MACD
  • MEIP 0.03
  • MXC 0.10
  • Stochastic Oscillator
  • MEIP 100.00
  • MXC 55.88

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About MXC Mexco Energy Corporation

Mexco Energy Corporation is an independent oil and gas company. It is engaged in the exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.

Share on Social Networks: